{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:45:43Z","timestamp":1785703543224,"version":"3.56.0"},"reference-count":209,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019305","name":"Manipal Academy of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004318","name":"Microsoft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bbrc.2026.154083","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:19:15Z","timestamp":1780355955000},"page":"154083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Precision targeting of SRC signaling in glioblastoma: Mechanistic insights and bilosome nanotechnology"],"prefix":"10.1016","volume":"828","author":[{"given":"Manjunath","family":"Madalageri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeresh","family":"Sadashivanavar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Kinnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-856X","authenticated-orcid":false,"given":"Kokou","family":"Atchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-9533","authenticated-orcid":false,"given":"K.","family":"Sreedhara Ranganath Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154083_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.bbrc.2026.154083_bib2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/35077225","article-title":"Oncogenic kinase signalling","volume":"411","author":"Blume-Jensen","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1084\/jem.13.4.397","article-title":"A SARCOMA of the fowl transmissible by an agent separable from the tumor cells","volume":"13","author":"Rous","year":"1911","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/2271021a0","article-title":"Rous sarcoma virus: a function required for the maintenance of the transformed state","volume":"227","author":"Martin","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/260170a0","article-title":"DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA","volume":"260","author":"Stehelin","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0959-440X(97)80146-7","article-title":"Structures of Src-family tyrosine kinases","volume":"7","author":"Sicheri","year":"1997","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2011\/865819","article-title":"Regulation of src family kinases in human cancers","volume":"2011","author":"Sen","year":"2011","journal-title":"J. Signal Transduct."},{"key":"10.1016\/j.bbrc.2026.154083_bib11","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1038\/sj.onc.1203923","article-title":"Selected glimpses into the activation and function of src kinase","volume":"19","author":"Bjorge","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2010.08.014","article-title":"Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies","volume":"298","author":"Ahluwalia","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154083_bib13","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1158\/0008-5472.CAN-04-3688","article-title":"Lyn kinase activity is the predominant cellular src kinase activity in glioblastoma tumor cells","volume":"65","author":"Stettner","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib14","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nbt.1513","article-title":"Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy","volume":"27","author":"Du","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154083_bib15","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","article-title":"Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?","volume":"114","author":"Branford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib16","first-page":"415","article-title":"Pharmaceutical approval update","volume":"39","author":"Goldenberg","year":"2014","journal-title":"P T"},{"key":"10.1016\/j.bbrc.2026.154083_bib17","article-title":"Ponatinib: an update on its drug targets, therapeutic potential and safety","volume":"1878","author":"Gao","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.154083_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-021-01479-0","article-title":"Tirbanibulin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2026.154083_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117369","article-title":"Advancing src kinase inhibition: from structural design to therapeutic innovation - a comprehensive review","volume":"287","author":"Su","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein Corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154083_bib21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mam.2013.06.004","article-title":"Brain tumor stem cells: molecular characteristics and their impact on therapy","volume":"39","author":"Schonberg","year":"2014","journal-title":"Mol. Aspect. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib22","article-title":"Nanomedicine revisited: next generation therapies for brain cancer","volume":"3","author":"Bhargav","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bbrc.2026.154083_bib23","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154083_bib24","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/neuonc\/nov319","article-title":"Epidermal growth factor receptor targeting and challenges in glioblastoma","volume":"18","author":"Thorne","year":"2016","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib25","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","article-title":"Imatinib","volume":"61","author":"Lyseng-Williamson","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2026.154083_bib26","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154083_bib28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1478-811X-11-97","article-title":"Targeting the PDGF signaling pathway in tumor treatment","volume":"11","author":"Heldin","year":"2013","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2026.154083_bib29","first-page":"272","article-title":"Biology of platelet\u2010derived growth factors in development, Birth Defects Res","volume":"69","author":"Betsholtz","year":"2003","journal-title":"C Embryo Today"},{"key":"10.1016\/j.bbrc.2026.154083_bib30","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drup.2005.03.004","article-title":"Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics","volume":"8","author":"Board","year":"2005","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.bbrc.2026.154083_bib31","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbrc.2026.154083_bib32","doi-asserted-by":"crossref","first-page":"F79","DOI":"10.1016\/S0304-419X(98)00015-8","article-title":"Signal transduction via platelet-derived growth factor receptors","volume":"1378","author":"Heldin","year":"1998","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.154083_bib33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0304-419X(96)00003-0","article-title":"Regulation, substrates and functions of src","volume":"1287","author":"Brown","year":"1996","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.154083_bib34","first-page":"2383","article-title":"Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours","volume":"9","author":"Mitchell","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib35","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.molonc.2015.06.001","article-title":"Src family kinases differentially influence glioma growth and motility","volume":"9","author":"Lewis-Tuffin","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.tips.2011.11.002","article-title":"Targeting Src family kinases in anti-cancer therapies: turning promise into triumph","volume":"33","author":"Zhang","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib37","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/nrc1366","article-title":"A renaissance for SRC","volume":"4","author":"Yeatman","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154083_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1006\/bbrc.1997.8043","article-title":"Overexpression and activation of the tyrosine kinase src in human pancreatic carcinoma","volume":"243","author":"Lutz","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154083_bib39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1083\/jcb.200206049","article-title":"PTP\u03b1 regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration","volume":"160","author":"Zeng","year":"2003","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbrc.2026.154083_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1158\/1541-7786.MCR-05-0015","article-title":"Crk-Associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of src-transformed cells","volume":"3","author":"Br\u00e1bek","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0014-5793(00)02354-1","article-title":"SRC transcriptional activation in a subset of human colon cancer cell lines","volume":"487","author":"Dehm","year":"2001","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbrc.2026.154083_bib43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1139\/o03-077","article-title":"SRC gene expression in human cancer: the role of transcriptional activation","volume":"82","author":"Dehm","year":"2004","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib44","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1038\/sj.onc.1203912","article-title":"Role of Src expression and activation in human cancer","volume":"19","author":"Irby","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib45","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/5971","article-title":"Activating SRC mutation in a subset of advanced human colon cancers","volume":"21","author":"Irby","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154083_bib46","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib47","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1073\/pnas.131568898","article-title":"Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis","volume":"98","author":"Bowman","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1006\/excr.1999.4669","article-title":"Multiple roles for src in a PDGF-stimulated cell","volume":"253","author":"DeMali","year":"1999","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib49","first-page":"2027","article-title":"Fibroblast growth factor receptor-1 regulation of Src family kinases","volume":"10","author":"Landgren","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib50","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/sj.onc.1201496","article-title":"Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential","volume":"15","author":"Mao","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib51","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1158\/0008-5472.CAN-05-4340","article-title":"Ionizing radiation enhances matrix Metalloproteinase-2 secretion and invasion of glioma cells through Src\/Epidermal growth factor receptor\u2013mediated p38\/Akt and phosphatidylinositol 3-Kinase\/Akt signaling pathways","volume":"66","author":"Park","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bst0300011","article-title":"Role of src in signal transduction pathways","volume":"30","author":"Courtneidge","year":"2002","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bbrc.2026.154083_bib53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1042\/bj3370171","article-title":"Platelet-derived-growth-factor stimulation of the p42\/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase","volume":"337","author":"Conway","year":"1999","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2026.154083_bib54","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/emboj\/21.4.514","article-title":"c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis","volume":"21","author":"Furstoss","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2026.154083_bib55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1074\/jbc.M107110200","article-title":"Activation of extracellular signal-regulated kinase by ultraviolet is mediated through src-dependent epidermal growth factor receptor phosphorylation","volume":"277","author":"Kitagawa","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061558","article-title":"SRC kinase in Glioblastoma News from an old acquaintance","volume":"12","author":"Cirotti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154083_bib57","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1158\/0008-5472.CAN-14-2345","article-title":"Src inhibition blocks c-Myc translation and glucose metabolism to prevent the development of breast cancer","volume":"75","author":"Jain","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib58","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41419-018-0419-y","article-title":"SLIT2\/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC\/ERK\/c-MYC\/PFKFB2 pathway","volume":"9","author":"Zhao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154083_bib59","doi-asserted-by":"crossref","first-page":"25113","DOI":"10.18632\/oncotarget.7159","article-title":"Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation","volume":"7","author":"Jin","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.154083_bib60","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/j.celrep.2017.11.022","article-title":"Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence","volume":"21","author":"Singleton","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2026.154083_bib61","doi-asserted-by":"crossref","unstructured":"Q.P. Ly, T.J. Yeatman, Clinical relevance of targeted interference with src-mediated signal transduction events, in: Targeted Interference with Signal Transduction Events, Springer Berlin Heidelberg, Berlin, Heidelberg, n.d.: pp. 169\u2013188. https:\/\/doi.org\/10.1007\/978-3-540-31209-3_10.","DOI":"10.1007\/978-3-540-31209-3_10"},{"key":"10.1016\/j.bbrc.2026.154083_bib62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/1097-0215(20001101)88:3<384::AID-IJC10>3.0.CO;2-B","article-title":"Overexpression of thecsk gene suppresses tumor metastasisin vivo","volume":"88","author":"Nakagawa","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154083_bib63","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/sj.onc.1202233","article-title":"Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530","volume":"18","author":"Egan","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib64","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1038\/sj.onc.1208080","article-title":"The interplay between Src and integrins in normal and tumor biology","volume":"23","author":"Playford","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib65","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1128\/MCB.24.17.7578-7597.2004","article-title":"Protein kinase C\u03b1 activates c-Src and induces podosome formation via AFAP-110","volume":"24","author":"Gatesman","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib66","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0304-419X(02)00040-9","article-title":"Src in cancer: deregulation and consequences for cell behaviour","volume":"1602","author":"Frame","year":"2002","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.bbrc.2026.154083_bib67","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.onc.1205260","article-title":"Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis","volume":"21","author":"Niu","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1042\/bj3600255","article-title":"Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells","volume":"360","author":"Abu-Ghazaleh","year":"2001","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2026.154083_bib69","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.tem.2015.09.013","article-title":"Protein phosphorylation: a major switch mechanism for metabolic regulation","volume":"26","author":"Humphrey","year":"2015","journal-title":"Trends Endocrinol. Metabol."},{"key":"10.1016\/j.bbrc.2026.154083_bib70","article-title":"c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154083_bib71","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/metabo9120282","article-title":"Glucose-6 phosphate, a central hub for liver carbohydrate metabolism","volume":"9","author":"Rajas","year":"2019","journal-title":"Metabolites"},{"key":"10.1016\/j.bbrc.2026.154083_bib72","first-page":"1492","article-title":"Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes","volume":"235","author":"Flier","year":"1987","journal-title":"Science (1979)"},{"key":"10.1016\/j.bbrc.2026.154083_bib73","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1074\/jbc.M117.816785","article-title":"Hexokinase 2 and nuclear factor erythroid 2\u2013related factor 2 transcriptionally coactivate xanthine oxidoreductase expression in stressed glioma cells","volume":"293","author":"Sheikh","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1084\/jem.20101470","article-title":"Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme","volume":"208","author":"Wolf","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib75","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2017-10-809210","article-title":"Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in Non-Hodgkin lymphoma","volume":"131","author":"Battistello","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152932","article-title":"Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression","volume":"62","author":"Bhummaphan","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bbrc.2026.154083_bib77","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib78","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1215\/15228517-2008-113","article-title":"Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts","volume":"11","author":"Hodgson","year":"2009","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib79","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1038\/ncomms5632","article-title":"Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis","volume":"5","author":"Annibali","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154083_bib80","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1242\/jcs.024802","article-title":"Myc increases self-renewal in neural progenitor cells through Miz-1","volume":"121","author":"Kerosuo","year":"2008","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib81","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1158\/1078-0432.CCR-15-2274","article-title":"Myc-Driven glycolysis is a therapeutic target in glioblastoma","volume":"22","author":"Tateishi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib82","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0167-4889(02)00174-X","article-title":"Characterization and location of src-dependent tyrosine phosphorylation in rat brain mitochondria","volume":"1589","author":"Salvi","year":"2002","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib83","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41419-019-2134-8","article-title":"Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells","volume":"10","author":"Djeungoue-Petga","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154083_bib84","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.3109\/10715762.2015.1050013","article-title":"Mitochondrial Src tyrosine kinase plays a role in the cardioprotective effect of ischemic preconditioning by modulating complex I activity and mitochondrial ROS generation","volume":"49","author":"Ge","year":"2015","journal-title":"Free Radic. Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib85","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/jcb.21670","article-title":"Src\u2010Tyrosine kinases are major agents in mitochondrial tyrosine phosphorylation","volume":"104","author":"Tibaldi","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2026.154083_bib86","doi-asserted-by":"crossref","first-page":"36592","DOI":"10.1074\/jbc.M109.000760","article-title":"Epidermal growth factor receptor translocation to the Mitochondria","volume":"284","author":"Demory","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib87","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.freeradbiomed.2005.02.006","article-title":"Tyrosine phosphorylation in mitochondria: a new frontier in mitochondrial signaling","volume":"38","author":"Salvi","year":"2005","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib88","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bbabio.2012.01.014","article-title":"Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10","volume":"1817","author":"Hebert-Chatelain","year":"2012","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"10.1016\/j.bbrc.2026.154083_bib89","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1242\/jcs.083295","article-title":"Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism","volume":"124","author":"Cvrljevic","year":"2011","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1368-7646(02)00120-6","article-title":"Activation of the PI3K\/Akt pathway and chemotherapeutic resistance","volume":"5","author":"West","year":"2002","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.bbrc.2026.154083_bib91","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0065-230X(05)94002-5","article-title":"Activation of AKT kinases in cancer: implications for therapeutic targeting","volume":"94","author":"Bellacosa","year":"2005","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib92","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined src and aromatase inhibition impairs human breast cancer growth In vivo and bypass pathways are activated in AZD0530-Resistant tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib93","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib94","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)\u2013based mutagenesis screen: high efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib96","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/s41467-024-51444-0","article-title":"The proto-oncogene tyrosine kinase c-SRC facilitates glioblastoma progression by remodeling fatty acid synthesis","volume":"15","author":"Zhao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154083_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111311","article-title":"Resistance to spindle inhibitors in glioblastoma depends on STAT3 and therapy induced senescence","volume":"27","author":"Zarco","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154083_bib98","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202302205","article-title":"NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma","volume":"7","author":"Cirotti","year":"2024","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.bbrc.2026.154083_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2023.1325214","article-title":"Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment","volume":"11","author":"Rahban","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/cancers16010032","article-title":"Role of c-Src in carcinogenesis and drug resistance","volume":"16","author":"Raji","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2026.154083_bib101","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N -(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib102","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/1535-7163.MCT-08-0669","article-title":"Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma","volume":"8","author":"Milano","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2026.154083_bib103","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1074\/jbc.271.2.695","article-title":"Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor: STUDY OF Lck- AND FynT-DEPENDENT T CELL ACTIVATION","volume":"271","author":"Hanke","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib104","first-page":"511","article-title":"Src regulates phorbol 12-myristate 13-acetate-activated PKC-induced migration via Cas\/Crk\/Rac1 signaling pathway in glioblastoma cells","volume":"20","author":"Nomura","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ijrobp.2005.11.014","article-title":"SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation","volume":"64","author":"Cuneo","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbrc.2026.154083_bib106","doi-asserted-by":"crossref","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","article-title":"In vitro and In vivo activity of SKI-606, a novel src-abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells","volume":"66","author":"Puttini","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib107","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","article-title":"Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530","volume":"3","author":"Green","year":"2009","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib108","series-title":"Neuro. Oncol.","first-page":"824","article-title":"Phase II trial of dasatinib for recurrent glioblastoma (RTOG 0627)","author":"Lassman","year":"2008"},{"key":"10.1016\/j.bbrc.2026.154083_bib109","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome\u2013positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2026.154083_bib110","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","article-title":"Saracatinib, a selective src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis","volume":"206","author":"Ahangari","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib111","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-23-0709","article-title":"Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and src family kinase YES in Rhabdomyosarcoma","volume":"29","author":"Akshintala","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib112","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41416-019-0428-3","article-title":"Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance","volume":"120","author":"Creelan","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154083_bib113","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3390\/tomography7020013","article-title":"Whole-Body [18F]-Fluoride PET SUV imaging to monitor response to dasatinib therapy in castration-resistant prostate cancer bone metastases: secondary results from ACRIN 6687","volume":"7","author":"Muzi","year":"2021","journal-title":"Tomography"},{"key":"10.1016\/j.bbrc.2026.154083_bib114","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90449","article-title":"Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer","volume":"2","author":"Bauman","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2026.154083_bib115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/7935475","article-title":"Results of a randomized, double-blinded, placebo-controlled, phase 2.5 study of saracatinib (AZD0530), in patients with recurrent osteosarcoma localized to the lung","volume":"2020","author":"Baird","year":"2020","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbrc.2026.154083_bib116","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-12-0507","article-title":"A phase I trial of dasatinib, an src-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer","volume":"18","author":"Secord","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib117","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1200\/JCO.2009.25.4029","article-title":"Phase I\/II study of the src inhibitor dasatinib in combination with erlotinib in advanced Non\u2013small-cell lung cancer","volume":"28","author":"Haura","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib118","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib119","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12964-021-00750-x","article-title":"Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition","volume":"19","author":"Ortiz","year":"2021","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.bbrc.2026.154083_bib120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s11060-014-1667-z","article-title":"Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma","volume":"121","author":"Taylor","year":"2015","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib121","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/jpet.117.243477","article-title":"Heterogeneous binding and central nervous system distribution of the multitargeted kinase inhibitor ponatinib restrict orthotopic efficacy in a patient-derived xenograft model of glioblastoma","volume":"363","author":"Laramy","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.bbrc.2026.154083_bib122","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1002\/cam4.2505","article-title":"Phase II trial of ponatinib in patients with bevacizumab\u2010refractory glioblastoma","volume":"8","author":"Lee","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbrc.2026.154083_bib123","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1593\/neo.10328","article-title":"SRC: a century of science brought to the clinic","volume":"12","author":"Aleshin","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.bbrc.2026.154083_bib124","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1158\/1535-7163.MCT-09-1212","article-title":"Targeted inhibition of src kinase signaling attenuates pancreatic tumorigenesis","volume":"9","author":"Nagaraj","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrc.2026.154083_bib125","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1634\/theoncologist.2013-0255","article-title":"Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas","volume":"18","author":"Chee","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbrc.2026.154083_bib126","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1091\/mbc.e10-08-0700","article-title":"\u03b23 Integrin\u2013EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells","volume":"22","author":"Balanis","year":"2011","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib127","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1083\/jcb.132.4.741","article-title":"Stimulation of beta1 integrins on fibroblasts induces PDGF independent tyrosine phosphorylation of PDGF beta-receptors","volume":"132","author":"Sundberg","year":"1996","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib128","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1091\/mbc.6.10.1349","article-title":"Convergence of integrin and growth factor receptor signaling pathways within the focal adhesion complex","volume":"6","author":"Plopper","year":"1995","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib129","doi-asserted-by":"crossref","first-page":"26613","DOI":"10.1074\/jbc.270.44.26613","article-title":"p80\/85 cortactin associates with the src SH2 domain and colocalizes with v-Src in transformed cells","volume":"270","author":"Okamura","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib130","doi-asserted-by":"crossref","first-page":"7696","DOI":"10.1073\/pnas.90.16.7696","article-title":"The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells","volume":"90","author":"Twamley-Stein","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib131","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/378509a0","article-title":"Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src","volume":"378","author":"Barone","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib132","doi-asserted-by":"crossref","first-page":"24427","DOI":"10.1016\/S0021-9258(20)80543-2","article-title":"Murine cortactin is phosphorylated in response to fibroblast growth factor-1 on tyrosine residues late in the G1 phase of the BALB\/c 3T3 cell cycle","volume":"268","author":"Zhan","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib133","doi-asserted-by":"crossref","first-page":"20221","DOI":"10.1016\/S0021-9258(17)31978-6","article-title":"Association of fibroblast growth factor receptor-1 with c-Src correlates with association between c-Src and cortactin","volume":"269","author":"Zhan","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib134","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0092-8674(00)81604-9","article-title":"A requirement for Caveolin-1 and associated kinase fyn in integrin signaling and anchorage-dependent cell growth","volume":"94","author":"Wary","year":"1998","journal-title":"Cell"},{"issue":"1995","key":"10.1016\/j.bbrc.2026.154083_bib135","first-page":"1567","article-title":"Requirement for src family protein tyrosine kinases in G 2 for fibroblast cell division","volume":"269","author":"Roche","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2026.154083_bib136","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/368867a0","article-title":"An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis","volume":"368","author":"Taylor","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib137","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/368871a0","article-title":"A target for Src in mitosis","volume":"368","author":"Fumagalli","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib138","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0039-6060(97)90002-7","article-title":"Activation of pp60c-src is necessary for human vascular smooth muscle cell migration","volume":"122","author":"Mureebe","year":"1997","journal-title":"Surgery"},{"key":"10.1016\/j.bbrc.2026.154083_bib139","first-page":"1487","article-title":"Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from mitosis of Src-transformed cells","volume":"7","author":"Pillay","year":"1996","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.bbrc.2026.154083_bib140","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1128\/MCB.18.4.2014","article-title":"Activation of src family members is not required for the platelet-derived growth factor \u03b2 receptor to initiate mitogenesis","volume":"18","author":"DeMali","year":"1998","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib141","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1074\/jbc.273.10.5908","article-title":"A role for src in signal relay by the platelet-derived growth factor \u03b1 receptor","volume":"273","author":"Gelderloos","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib142","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1002\/j.1460-2075.1993.tb05879.x","article-title":"Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases","volume":"12","author":"Mori","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2026.154083_bib143","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1074\/jbc.273.27.17050","article-title":"Full activation of the platelet-derived growth factor \u03b2-Receptor kinase involves multiple events","volume":"273","author":"Baxter","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib144","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1038\/sj.onc.1202694","article-title":"STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation","volume":"18","author":"Sachsenmaier","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib145","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/343377a0","article-title":"Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases","volume":"343","author":"Ellis","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib146","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.89.19.8869","article-title":"Shc proteins are phosphorylated and regulated by the v-Src and v-Fps protein-tyrosine kinases","volume":"89","author":"McGlade","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib147","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1073\/pnas.88.12.5453","article-title":"CD3 stimulation causes phosphorylation of phospholipase C-gamma 1 on serine and tyrosine residues in a human T-cell line","volume":"88","author":"Park","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib148","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.1073\/pnas.88.13.5484","article-title":"Functional activation of the T-cell antigen receptor induces tyrosine phosphorylation of phospholipase C-gamma 1","volume":"88","author":"Weiss","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib149","doi-asserted-by":"crossref","first-page":"28335","DOI":"10.1074\/jbc.274.40.28335","article-title":"Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth Factor-AA-dependent chemotaxis and DNA synthesis","volume":"274","author":"Rosenkranz","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1242\/jcs.111.5.607","article-title":"PDGF \u03b1-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells","volume":"111","author":"Hooshmand-Rad","year":"1998","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib151","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/emboj\/18.9.2459","article-title":"Src family kinases are required for integrin but not PDGFR signal transduction","volume":"18","author":"Klinghoffer","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2026.154083_bib152","doi-asserted-by":"crossref","first-page":"16798","DOI":"10.1074\/jbc.271.28.16798","article-title":"Requirement for c-Src catalytic activity and the SH3 domain in platelet-derived growth factor BB and epidermal growth factor mitogenic signaling","volume":"271","author":"Broome","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib153","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/367474a0","article-title":"Regulation of chemotaxis by the platelet-derived growth factor receptor-\u03b2","volume":"367","author":"Kundra","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154083_bib154","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1083\/jcb.130.3.725","article-title":"The chemotactic response to PDGF-BB: evidence of a role for Ras","volume":"130","author":"Kundra","year":"1995","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib155","first-page":"1429","article-title":"Excess early signaling activity inhibits cellular chemotaxis toward PDGF-BB","volume":"9","author":"Kundra","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib156","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1749-6632.1995.tb26691.x","article-title":"Platelet-derived growth factor. Distinct signal transduction pathways associated with migration versus proliferation","volume":"766","author":"Bornfeldt","year":"1995","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib157","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1073\/pnas.82.23.7845","article-title":"The product of the protooncogene c-src is modified during the cellular response to platelet-derived growth factor","volume":"82","author":"Ralston","year":"1985","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bbrc.2026.154083_bib158","first-page":"3345","article-title":"Platelet-Derived growth factor induces multisite phosphorylation of pp60 c- src and increases its protein-tyrosine kinase activity","volume":"8","author":"Gould","year":"1988","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2026.154083_bib159","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(88)90422-9","article-title":"Altered phosphorylation and activation of PP60c-src during fibroblast mitosis","volume":"52","author":"Chackalaparampil","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib160","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/0092-8674(90)90013-5","article-title":"Association between the PDGF receptor and members of the src family of tyrosine kinases","volume":"62","author":"Kypta","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154083_bib161","first-page":"1893","article-title":"Association of Fyn with the activated platelet-derived growth factor receptor: requirements for binding and phosphorylation","volume":"7","author":"Twamley","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2026.154083_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114367","article-title":"Opportunities for improving brain cancer treatment outcomes through imaging-based mathematical modeling of the delivery of radiotherapy and immunotherapy","volume":"187","author":"Hormuth","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrc.2026.154083_bib163","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3233\/THC-191845","article-title":"Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants","volume":"28","author":"Kecman","year":"2020","journal-title":"Technol. Health Care"},{"key":"10.1016\/j.bbrc.2026.154083_bib164","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40005-020-00491-y","article-title":"High frequency ultrasound mediated transdermal delivery of ondansetron hydrochloride employing bilosomal gel systems: ex-vivo and in-vivo characterization studies","volume":"50","author":"Ammar","year":"2020","journal-title":"J. Pharm. Investig."},{"key":"10.1016\/j.bbrc.2026.154083_bib165","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/B978-0-323-91864-0.00004-8","article-title":"Bilosomes: a novel platform for drug delivery","author":"Gupta","year":"2022","journal-title":"Syst. Nanovesic. Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib166","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/1574885514666190917145510","article-title":"Bilosomes: superior vesicular carriers","volume":"15","author":"Palekar-Shanbhag","year":"2020","journal-title":"Curr. Drug Ther."},{"key":"10.1016\/j.bbrc.2026.154083_bib167","article-title":"Bile salt stabilized nanovesicles as a promising drug delivery technology: a general overview and future perspectives","volume":"79","author":"Abdel-moneum","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.154083_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01283","article-title":"Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles","volume":"9","author":"Pavlovi\u0107","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154083_bib169","article-title":"Bilosomes nanocarriers for improved oral bioavailability of acyclovir: a complete characterization through in vitro, ex-vivo and in vivo assessment","volume":"57","author":"Rizwanullah","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.154083_bib170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.4155\/tde-2017-0082","article-title":"Implantable systems for drug delivery to the brain","volume":"8","author":"Kaurav","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib171","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.drudis.2006.10.013","article-title":"Blood\u2013brain barrier delivery","volume":"12","author":"Pardridge","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2026.154083_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrc.2026.154083_bib174","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1124\/mol.63.3.742","article-title":"Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors","volume":"63","author":"Briz","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154083_bib175","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/08982104.2018.1551408","article-title":"Dextrose modified bilosomes for peroral delivery: improved therapeutic potential and stability of silymarin in diethylnitrosamine-induced hepatic carcinoma in rats","volume":"29","author":"Parashar","year":"2019","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib176","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1080\/10717544.2021.2008055","article-title":"Development and evaluation of luteolin loaded pegylated bilosome: optimization, in vitro characterization, and cytotoxicity study","volume":"28","author":"Zafar","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib177","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/polym14050921","article-title":"Formulation of chitosan-coated apigenin bilosomes: in vitro characterization, antimicrobial and cytotoxicity assessment","volume":"14","author":"Imam","year":"2022","journal-title":"Polymers"},{"key":"10.1016\/j.bbrc.2026.154083_bib178","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/10717544.2022.2044938","article-title":"Development and optimization of curcumin analog nano-bilosomes using 2 1 .3 1 full factorial design for anti-tumor profiles improvement in human hepatocellular carcinoma: in-vitro evaluation, in-vivo safety assay","volume":"29","author":"Abbas","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib179","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3390\/ph14121309","article-title":"Development of an icariin-loaded bilosome-melittin formulation with improved anticancer activity against cancerous pancreatic cells","volume":"14","author":"Alhakamy","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2026.154083_bib180","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1080\/10717544.2022.2120925","article-title":"Pitavastatin-loaded bilosomes for oral treatment of hepatocellular carcinoma: a repurposing approach","volume":"29","author":"Kharouba","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib181","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1080\/10717544.2022.2122634","article-title":"Development of surface modified bilosomes for the oral delivery of quercetin: optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study","volume":"29","author":"Alruwaili","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154083_bib182","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/ph14101021","article-title":"Design and synthesis of newly synthesized acrylamide derivatives as potential chemotherapeutic agents against MCF-7 breast cancer cell line lodged on PEGylated bilosomal nano-vesicles for improving cytotoxic activity","volume":"14","author":"Zaki","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2026.154083_bib183","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/03639045.2017.1402922","article-title":"Exploiting bilosomes for delivering bioactive polysaccharide isolated from Enteromorpha intestinalis for hacking hepatocellular carcinoma","volume":"44","author":"Matloub","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.bbrc.2026.154083_bib173","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/pharmaceutics16060697","article-title":"Emerging trends in bilosomes as therapeutic drug delivery systems","volume":"16","author":"Kaurav","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154083_bib184","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/2211738510666211222111938","article-title":"Recent advancements in nanodiamond mediated brain targeted drug delivery and bioimaging of brain ailments: a holistic review","volume":"10","author":"Singh","year":"2022","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.bbrc.2026.154083_bib185","doi-asserted-by":"crossref","first-page":"8482","DOI":"10.1166\/jnn.2010.2687","article-title":"Pharmacokinetics and physiologically-based pharmacokinetic modeling of nanoparticles","volume":"10","author":"Yang","year":"2010","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.bbrc.2026.154083_bib186","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/bdd.2331","article-title":"The role of the efflux transporter, P\u2010glycoprotein, at the blood\u2013brain barrier in drug discovery, Biopharm","volume":"44","author":"Cox","year":"2023","journal-title":"Drug Dispos."},{"key":"10.1016\/j.bbrc.2026.154083_bib187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17435390.2021.1924888","article-title":"Cabazitaxel-loaded poly(alkyl cyanoacrylate) nanoparticles: toxicity and changes in the proteome of breast, colon and prostate cancer cells","author":"\u00d8verbye","year":"2021","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.bbrc.2026.154083_bib188","first-page":"6189","article-title":"Cytotoxic effect of Nano-SiO2 in human breast cancer cells via modulation of EGFR signaling cascades","volume":"37","author":"Jeon","year":"2017","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib189","doi-asserted-by":"crossref","first-page":"7831","DOI":"10.2147\/IJN.S470005","article-title":"Bufalin-loaded multifunctional photothermal nanoparticles inhibit the anaerobic glycolysis by targeting SRC-3\/HIF-1\u03b1 pathway for improved mild photothermal therapy in CRC","volume":"19","author":"Shang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2026.154083_bib190","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/acs.bioconjchem.8b00481","article-title":"Drug \u201cClicking\u201d on cell-penetrating fluorescent nanoparticles for In Cellulo chemical proteomics","volume":"29","author":"Valero","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bbrc.2026.154083_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.crbiot.2024.100213","article-title":"Let-7b miRNA-loaded nanostructures inhibited human tongue squamous cell carcinoma metastasis by the MOR-SRC-EGFR axis","volume":"7","author":"Yang","year":"2024","journal-title":"Curr. Res. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154083_bib192","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1158\/0008-5472.CAN-14-0795","article-title":"miR-124 and androgen receptor signaling inhibitors repress prostate cancer growth by downregulating androgen receptor splice variants, EZH2, and src","volume":"75","author":"Shi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib193","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3390\/pharmaceutics15020662","article-title":"Cabazitaxel-loaded nanoparticles reduce the invasiveness in metastatic prostate cancer cells: beyond the classical taxane function","volume":"15","author":"Lampe","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154083_bib194","doi-asserted-by":"crossref","first-page":"9291","DOI":"10.1007\/s00210-025-03829-1","article-title":"Bovine serum albumin nanoparticles encapsulating Dasatinib and Celecoxib for oral cancer: preparation, characterization, and in-vitro evaluation","volume":"398","author":"Aly","year":"2025","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.bbrc.2026.154083_bib195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/IJN.S148487","article-title":"Inhibition of cancer cell migration with CuS@mSiO2-PEG nanoparticles by repressing MMP-2\/MMP-9 expression","volume":"13","author":"Deng","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.bbrc.2026.154083_bib196","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-019-0827-1","article-title":"Simultaneously inactivating Src and AKT by saracatinib\/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma","volume":"12","author":"Lang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154083_bib197","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.7314\/APJCP.2012.13.5.2235","article-title":"c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the Human HT-29 Colon cancer cell line","volume":"13","author":"Nourazarian","year":"2012","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.bbrc.2026.154083_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122018","article-title":"Bufalin exacerbates photodynamic therapy of colorectal cancer by targeting SRC-3\/HIF-1\u03b1 pathway","volume":"624","author":"Yuan","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2026.154083_bib199","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/1078-0432.CCR-10-2081","article-title":"Functional roles of src and fgr in ovarian carcinoma","volume":"17","author":"Kim","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154083_bib200","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3390\/pharmaceutics13101635","article-title":"The tragedy of alzheimer's disease: towards better management via resveratrol-loaded oral bilosomes","volume":"13","author":"Abbas","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154083_bib201","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121244","article-title":"Superparamagnetic iron oxide loaded chitosan coated bilosomes for magnetic nose to brain targeting of resveratrol","volume":"610","author":"Abbas","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bbrc.2026.154083_bib202","doi-asserted-by":"crossref","first-page":"576","DOI":"10.3390\/pharmaceutics14030576","article-title":"A brain-targeted approach to ameliorate memory disorders in a sporadic alzheimer's disease mouse model via intranasal Luteolin-loaded nanobilosomes","volume":"14","author":"Elsheikh","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154083_bib203","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3390\/pharmaceutics13111828","article-title":"Intranasal zolmitriptan-loaded bilosomes with extended nasal mucociliary transit time for direct nose to brain delivery","volume":"13","author":"El Taweel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154083_bib204","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1055\/s-0042-1757969","article-title":"Bilosomes as a potential carrier to enhance cognitive effects of Bacopa monnieri extract on oral administration","volume":"13","author":"Narayanan","year":"2023","journal-title":"J. Health Allied Sci. NU"},{"key":"10.1016\/j.bbrc.2026.154083_bib205","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/gels8110687","article-title":"Development of ciprofloxacin-loaded bilosomes In-Situ gel for ocular delivery: optimization, In-Vitro characterization, Ex-Vivo permeation, and antimicrobial study","volume":"8","author":"Alsaidan","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.bbrc.2026.154083_bib206","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/gels8070418","article-title":"Formulation and evaluation of Moxifloxacin loaded bilosomes In-Situ gel: optimization to antibacterial evaluation","volume":"8","author":"Zafar","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.bbrc.2026.154083_bib207","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd2089","article-title":"Strategies for optimizing combinations of molecularly targeted anticancer agents","volume":"5","author":"Dancey","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbrc.2026.154083_bib208","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11060-009-9916-2","article-title":"Improving the prognosis for patients with glioblastoma: the rationale for targeting Src","volume":"95","author":"de Groot","year":"2009","journal-title":"J. Neuro Oncol."},{"issue":"2007","key":"10.1016\/j.bbrc.2026.154083_bib209","first-page":"287","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"1979","journal-title":"Science"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26008478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26008478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:46:50Z","timestamp":1785700010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26008478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":209,"alternative-id":["S0006291X26008478"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154083","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision targeting of SRC signaling in glioblastoma: Mechanistic insights and bilosome nanotechnology","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"154083"}}